Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye

NCT07740564 is registered in ClinicalTrials.gov with Ocumension Therapeutics (Suzhou) Co., Ltd as lead sponsor.

NCT NCT07740564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07740564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye
Lead sponsor
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
May 31, 2029
Enrollment
842 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye